Related Experiment Video
Updated: May 5, 2026
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
26.1K
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry
Esther Prados de la Torre1, Josefina Serrano1, Eva Barragán2,3
1University of Cordoba (UCO), Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Hematology Unit, Reina Sofia University Hospital, Cordoba, Spain.
Hematological Oncology
|January 9, 2026
Summary
This study found that CEBPA gene mutations occur in 6.1% of adult AML patients. CEBPA-bZIP mutations showed a similar overall survival to favorable ELN2024 risk patients.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- The CCAAT enhancer-binding protein alpha (CEBPA) gene is crucial in myeloid differentiation.
- Mutations in CEBPA are observed in acute myeloid leukemia (AML), but their incidence and prognostic significance require further elucidation.
- Understanding CEBPA mutation patterns is vital for refining AML classification and treatment strategies.
Purpose of the Study:
- To investigate the incidence, co-mutation landscape, and prognostic impact of CEBPA gene mutations in adult AML patients treated with non-intensive induction (non-IT) therapies.
- To analyze the co-occurrence of CEBPA mutations with other genetic alterations, particularly those related to myelodysplastic syndromes (MDS) and epigenetic regulation.
- To evaluate the overall survival (OS) outcomes associated with different types of CEBPA mutations, including those in the bZIP domain.
Main Methods:
- Analysis of a large, multicenter cohort of 1367 adult AML patients treated with non-IT modalities.
- Identification and categorization of CEBPA mutations, distinguishing between those in the bZIP domain and other regions.
- Co-mutation analysis with frequently altered genes (e.g., TET2, SRSF2, ASXL1) and assessment of mutation timing using the Bradley-Terry model.
- Prognostic evaluation of overall survival based on CEBPA mutation status and type, including comparisons with European LeukemiaNet (ELN) 2024 risk categories.
Main Results:
- CEBPA mutations were identified in 6.1% (83/1367) of adult non-IT AML patients.
- Mutations in the bZIP domain (CEBPA-bZIP) were found in 2.5% of patients, while other CEBPA mutations (other CEBPAmut) occurred in 3.6%.
- Frequent co-mutations included TET2 (45.8%), SRSF2 (42.2%), and ASXL1 (40.9%). Mutations in MDS-related genes, TP53, and epigenetic regulators appeared earlier than CEBPA mutations.
- CEBPA-bZIP patients exhibited a median OS of 11.6 months, comparable to favorable ELN2024 risk patients, particularly when treated with hypomethylating agents (HMAs). Other CEBPA mutations were associated with shorter OS (9.0 months).
Conclusions:
- CEBPA mutations are infrequent in adult non-IT AML, often co-occurring with MDS-related genes.
- CEBPA-bZIP mutations are associated with a favorable prognosis, similar to the ELN2024 favorable risk group, especially in patients treated with HMAs.
- These findings highlight the importance of CEBPA mutation status, particularly bZIP domain mutations, in predicting outcomes for AML patients receiving non-intensive therapy.
